Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A. Ascierto, Vanna Chiarion‐Sileni, Michele Guida et al.|Journal of Clinical Oncology|2022Cited by 231
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A. Ascierto, Giuseppe Palmieri, Milena Casula et al.|Nature Communications|2024Cited by 94
LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized studyP.A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci et al.|Annals of Oncology|2021Cited by 30
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A. Ascierto, Vanna Chiarion‐Sileni, Mario Mandalà et al.|NEJM Evidence|2024Cited by 13